Questions about Context therapeutics
What is Context therapeutics?
Context Therapeutics is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, dedicated to creating new medicines for hormone-responsive cancers and solid tumors. Their lead program is Apristor (Onapristone XR), an investigational Phase 2 drug for progesterone receptor positive metastatic breast and ovarian cancers, while they also advance CTX-030916 for uterine fibroids and endometriosis. The company is committed to developing next-generation T cell engaging bispecific antibody therapies to harness the immune system for targeted cancer eradication.
What specific bispecific antibody therapies are currently in development?
The company's pipeline includes CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody, and CT-202, a dual pH-dependent Nectin-4 x CD3 bispecific antibody. They are also developing a discovery-stage program targeting Sigma1. These innovative immunotherapeutic solutions are designed to transform the landscape of cancer care and improve outcomes for patients with difficult-to-treat solid tumors.
What do reviewers say about the team and service quality?
Some reviewers on Trustburn praise the team as highly professional and knowledgeable, noting that their expertise and dedication surpassed expectations. Customers have described the services as excellent and unmatched in quality, with many stating they were extremely satisfied with the results and the incredible experience provided by the company.
What is the current Trustburn rating and review history?
The Trustburn rating is 4 out of 5 stars from 9 reviews. The most recent reviews were posted in November 2023, with the oldest review from April 2023, showing a consistent pattern of high satisfaction among those who have used their services.
Where is the company located and how can it be contacted?
Context Therapeutics is located at 3025 Market Street in Philadelphia, Pennsylvania, with a contact address at 2001 Market Street Suite 3915, Unit 15. They can be reached by phone at 267.225.7416 or via email at info@contexttherapeutics.com.
Who are the key leadership figures and what is their background?
Senior Scientific Advisor Eric Butz, PhD, brings more than 25 years of innovative research and team leadership in academic and biotechnology settings. Chief Medical Officer Karen Chagin, MD, previously served as Senior Vice President of Early-Stage Development at Adaptimmune, playing a critical role in the development and approval of Tecelra for a solid tumor.
What do Reddit users discuss regarding the company's stock and future catalysts?
Some users on Reddit note that the company has $54M in cash and is positioned for potential upside, though stock prices have fluctuated significantly. Reddit discussions also highlight upcoming catalysts such as FDA Fast Track designations and phase 1 data for their T cell engaging bispecific antibodies in advanced ovarian cancer.
What recent clinical trial results and financial updates have been reported?
News articles report that Context Therapeutics has shown clinical activity in ovarian cancer, with CTIM-76 weekly dosing at 140-280 µg resulting in a 22% confirmed ORR and 56% confirmed DCR. Phase 1b initiation is expected in Q1 2027, with initial Q3W efficacy data anticipated in Q2 2027.
What recent partnerships and corporate activities have occurred?
The company entered into a license agreement amendment with BioAtla for CT-202, demonstrating active collaboration and strategic partnerships to advance their technology pipeline. They also participate in investor conferences and publish news updates regarding their progress from lab to clinic.
What is the core mission and approach of the company?
The company focuses on advancing the treatment of solid tumors through the development of next-generation T cell engaging bispecific antibody therapies. Their purpose is to help patients with cancer, believing it is possible to find a way to improve outcomes for those with difficult-to-treat conditions.
What are the primary areas of focus for the company?
Context Therapeutics is dedicated to creating new medicines for hormone-responsive cancers and advancing T cell engagers for solid tumors. They are committed to transforming the landscape of cancer care and improving outcomes for patients with difficult-to-treat solid tumors through innovative immunotherapeutic solutions.
How do investors and market participants view the company's recent performance?
Some users on Reddit mention that the company has been building steam and is positioned for more upside, while others note the stock fell hard after good phase 1 data. The company is actively managing its cash runway into mid-2027 while awaiting new catalysts to drive the price higher.
What is the official website of Context therapeutics?
The official website of Context therapeutics is contexttherapeutics.com.
Is Context therapeutics on social media?
Context therapeutics has official profiles on Linkedin.
AI-generated from reviews on this page. Verify anything important with the company directly.
The services provided by Context Therapeutics are excellent. The team is highly professional and knowledgeable. They have helped me tremendously in my journey towards better health. I highly recommend their services!
I am extremely satisfied with the services provided by Context Therapeutics. Their expertise and dedication surpassed all my expectations. Thank you!
I recently used their services and it was an incredible experience. The team was really helpful and the results were beyond my expectations. Highly recommended!
I have been a customer of Context Therapeutics for a while now, and I must say they are absolutely fantastic. The quality of their services is unmatched. Keep up the good work!
Context Therapeutics is simply amazing! They have helped me immensely. 🌟
The team at Context Therapeutics is truly outstanding! Their services have made a significant impact on my well-being. 🌟
Context Therapeutics is simply amazing! Their services have made a huge difference in my life. 🌟
I recently availed the services of this company and I must say they are doing a great job. I am extremely satisfied with the results. Highly recommended!
News
No news yet. This is where the business shares its own updates and press.
Photos
No photos yet. Photos shared by reviewers will show up here.
Widgets
Get the widget for your site →About Context therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor (Onapristone XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. In addition, Context is advancing CTX-030916, a potential best-in-class oral antiprogestin for the treatment of uterine fibroids and endometriosis, and a discovery-stage program targeting Sigma1.
- Website
- contexttherapeutics.com
- Address
- 3025 market street
- Categories
- Biotechnology